Document is current
Any future updates will be listed below
-
Authors
Frazier, Eric
Sabour, Ryan
Nguyen, Matthew D.
Le, Dao
Hanna, Ramy
- License Information
-
More Information
Article History
Received: 3 March 2025
Accepted: 26 August 2025
First Online: 1 September 2025
Declarations
:
: Our institution does not require ethical approval for reporting individual cases or case series.
: Written informed consent was obtained from the patient for their anonymized information to be published in this article.
: R.H. serves on the speaker’s bureau of Alexion Pharmaceuticals (Astra-Zeneca rare disease), Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GSK Pharmaceuticals, and Astra-Zeneca proper. He is a consultant for the above and Calliditas Pharmaceuticals. He has worked as a Principal investigator on trials with Otsuka, Alexion, Remegen, Roche, Apellis, Novartis, and Calliditas Pharmaceuticals. E.F., R.S., M.D.N., and D.L. declare that they have no competing interests.
